Novo Nordisk's Failed Heart Drug Trial Sets Up a Defining Week for the Danish Drugmaker
Published on 08/02/2026 at 09:40 | Redaktion boerse-global.de
The numbers tell a stark story. Novo Nordisk's shares closed Friday at €40.90, down 8.48% on the day and roughly 25% below the January peak of €54.86. But the more telling figure may be the one arriving Tuesday: the company's first-half earnings report, which will show whether the market's patience — already stretched thin by a string of pipeline disappointments — has finally run out.
The trigger for Friday's sell-off was the Phase 3 ZEUS trial, which tested Ziltivekimab in patients with arterial calcification, chronic kidney disease, and elevated inflammatory markers. The drug hit its biological target, inhibiting the IL-6 signaling pathway as designed. What it failed to do was deliver a statistically meaningful reduction in cardiovascular death, non-fatal heart attacks, or strokes compared with placebo.
Wall Street's response has been anything but uniform. Jefferies and Citi argue the sell-off overshoots the drug's actual contribution to Novo Nordisk's business — a point echoed by UBS, which calculated that Ziltivekimab represented just 1.7% of the company's net present value. UBS analyst Matthew Weston had previously modeled roughly $3 billion in peak sales for the drug, about 60% of the consensus expectation. Yet even he expects the market reaction to run two to three times larger than the pure valuation impact, arguing the failure compounds pressure on the broader research pipeline.
Jefferies goes further, calling the outcome "strategically negative." The bank notes that a successful Ziltivekimab could have generated more than $10 billion in annual revenue, and its failure leaves Novo Nordisk more dependent than ever on its obesity franchise and external innovation. For the trial to have been deemed a success, the drug needed to cut risk by at least 20%, according to Jefferies. J.P. Morgan, by contrast, left its rating unchanged.
Should investors sell immediately? Or is it worth buying Novo Nordisk?
The fallout extended beyond Novo Nordisk itself. Shares of Monte Rosa Therapeutics and BioAge Labs tumbled as investors reassessed similar anti-inflammatory programs. Citi reported that BioAge Labs fell more than 60% on the ZEUS news alone.
The timing could hardly be worse. Novo Nordisk reports first-half results on August 5, offering the first detailed look at how pricing pressure in weight-loss drugs, the rollout of the Wegovy tablet, and competition from Eli Lilly are shaping the business. The company has said the ZEUS setback doesn't change its 2026 profit guidance, though a non-cash impairment charge will hit the third quarter. Research chief Martin Holst Lange has sought to reassure investors that the failure won't alter the company's strategic commitment to cardiovascular research.
But this is not an isolated setback. The CagriSema study had already failed to outperform Eli Lilly's competing product, and two related Ziltivekimab trials — HERMES in heart failure patients and ARTEMIS following acute heart attacks — won't report until the first half of 2027. That leaves a long stretch with no obvious catalyst from the cardiovascular pipeline.
Legal clouds add to the gloom. A federal judge in Trenton will hear arguments on August 27 over Novo Nordisk's request for a preliminary injunction to halt Eli Lilly's nationwide advertising campaigns. Novo alleges Lilly's ads for Zepbound and Mounjaro rely on outdated comparative data. Separately, a US class action accusing Novo of misleading investors about the CagriSema study has been allowed to proceed in part, with a judge ruling that investors plausibly showed statements about tolerability and study design may have been misleading. The company's spokesman denies the allegations and vows a vigorous defense.
Novo Nordisk at a turning point? This analysis reveals what investors need to know now.
The stock now sits almost exactly on its 50-day moving average of €40.90, just above the 200-day average of €40.35. The 14-day RSI of 41.8 suggests the market has priced in the bad news without tipping into panic — neither oversold nor overbought. Of the 26 analysts covering the stock, 18 rate it a "hold," and the average price target implies just 4.45% upside from pre-sell-off levels.
Tuesday's earnings report will determine whether the stock stabilizes at this level or resumes its slide. The failed trial may represent only a small piece of Novo Nordisk's valuation, but it has underscored a larger vulnerability: how much of the company's future still rests on Ozempic and Wegovy — and how little the market trusts anything else in the pipeline to pick up the slack.
Ad
Novo Nordisk Stock: New Analysis - 2 August
Fresh Novo Nordisk information released. What's the impact for investors? Our latest independent report examines recent figures and market trends.
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
